Quantum BioPharma Advances Lucid-MS Phase 2 Trial with Thermo Fisher Partnership

Quantum BioPharma Ltd. (NASDAQ: QNTM) has entered into a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-21-302 (Lucid-MS) for multiple sclerosis. The agreement initiates formal study start-up activities following FDA clearance to proceed with the trial. Thermo Fisher will support study start-up and related clinical research services through its PPD Clinical Research Business. Quantum BioPharma said the randomized, double-blind, placebo-controlled Phase 2 trial will evaluate the efficacy, safety and tolerability of Lucid-MS in people with progressive forms of MS using clinical and radiological endpoints.

Lucid-MS is an investigational, first-in-class New Chemical Entity designed to provide neuroprotection by inhibiting demyelination through targeting protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. This mechanism could offer a novel approach for progressive forms of MS, which currently have limited treatment options. For a Texas-based audience, this development highlights the state's growing role in biotechnology innovation and clinical research. The trial's success could lead to new therapies for MS patients and reinforce Texas as a hub for life sciences investment.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD and spun out its OTC version to a company, Unbuzzd Wellness Inc., led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. This announcement matters because it signals progress in a potentially transformative therapy for multiple sclerosis, a disease affecting millions worldwide. The involvement of Thermo Fisher Scientific, a global leader in clinical research, lends credibility and resources to the trial. For Texas, the news underscores the state's attractiveness for biotech companies and could spur further economic activity in the life sciences sector. As the trial advances, it may attract additional investment and talent to the region, reinforcing Texas as a key player in biomedical innovation.

About BioMedWire, BioMedWire is a specialized communications platform with a focus on the latest developments in the Biotechnology, Biomedical Sciences and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. Other services include article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness. BMW is where breaking news, insightful content and actionable information converge. For more information, please visit www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.